Mirtagen (Mirtazapine)

Mirtazapine, the active ingredient in Mirtagen, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral formulation for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and is available by prescription only.

GNH USA supplies Mirtagen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Mirtazapine is used primarily in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves mood. - Depressive episodes with prominent anxiety: reduces anxiety associated with depression. - Depression with insomnia: helps improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness. - Increased appetite leading to weight gain. - Dry mouth. - Constipation. - Dizziness. - Orthostatic hypotension.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Serotonin syndrome, especially with other serotonergic agents. - Suicidal ideation, particularly in early treatment. - Severe hepatic dysfunction. - Uncontrolled hypertension. - Severe allergic reactions such as anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor weight: watch for significant weight gain. - Assess mood: screen for worsening depression or suicidal thoughts. - Evaluate liver function: adjust use in hepatic impairment. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Review concomitant CNS depressants: risk of enhanced sedation. - Store at below 25°C: keep in the original pack, protect from moisture.

Mirtazapine can interact with various medications, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - Strong CNS depressants (e.g., benzodiazepines, alcohol): excessive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels. - Antihypertensive drugs: additive hypotensive effect. - Alcohol: may enhance sedative properties.